EDAP TMS started a study on BPH treatment with Focal One HIFU from Investing.com

LYON, France – EDAP TMS SA (NASDAQ:EDAP), an Entwickler therapeutic ultrasound company, which is conducting a Clinical Phase I/II Study for the Bewertung Seiner Focal One robotergestützten high intensity focussing ultrasound (HIFU) technology for the treatment of benign prostatic hyperplasia (BPH) has started. The first patients were discussed during their studies.

If the study acts, it is one of the sponsored, progressive, multi-centre companies that employs a recognized academic department for prostate management in France during its studies. The first part of the research is that there are optimal treatment parameters, a BPH symptom with minimal treatment parameters. I know that patient recruitment is carried out in a different way, one of the assurance and Wirksamkeit parameters that are validated.

Dr. Harry Toledano, Head of Urology Abteilung at the Krankenhaus Martigues, has used the potential of HIFU Technology, who has conducted research into the development of Prostatakrebs technology over 15 years. There is talk that the technology of BPH patients has an invasive treatment option with rapid breathing of normal activities.

Ryan Rhodes, CEO of EDAP TMS, has affected the millions of people living with BPH with an invasive treatment. It is clear that Focal One has a loose core, the integrity of the harnesses and other critical structures are not there. The results of the study provide the basis for a clinical study in the United States in the coming years.

EDAP TMS is available on the market for long-term treatment for therapeutic ultra-damage and bietet for various pathologies, a simple prostatic diagnosis and treatment. The Unternehmen come into being and provide the Geräte zur Treatment of Harnsteinen.

The press conferences are aimed at excluding risks and the uninterested. These direct debits are carried out and carried out by the factory towers of the market of HIFU devices, including wiring and other risks included in the SEC regulation of the Unternehmens. In this article you will find information about a press conference of EDAP TMS SA.

In others, the EDAP TMS is one of the main revenues of 10.6% at US$15.8 million for the 2024 quarter reported. This Wachstum is great on the strong Leistung and zunehmende Akzeptanz Seiner Focal One HIFU Technology with the treatment of local prostatakrebszurückzuführen. This research has a significant impact on US clinical pictures and clinical research, both for prostate inhibitors and for benign prostatic hyperplasia (BPH).

I am near the Focal One system, including at City of Hope and Robert Wood Johnson University Hospital. The Phase III trial for robotic HIFU in the treatment of endometriosis trials likely failed the disease and work, and it is possible that the generation for a Phase I/II trial for Focal One HIFU in the treatment of BPH is being executed. It is a study of strategic analyzes and analyzes of urologically oriented scientific tags.

If you’re sitting on the beach, capital costs depend on business operations and F&E investments managed. The second part is about a quarter of the net surplus of 6.1 million euros, offering a small amount of volume and operational leasing, thus driving margins in the HIFU segment. Trotz dieser Herausforderungen said EDAP TMS weiterhin signal Engagement for the Weiterentwicklung blesser HIFU-Technologie and the Erweiterung blesser Marktpräsenz.

InvestingPro Insights

Während EDAP TMS SA (NASDAQ:EDAP) has initiated a Phase I/II study on the BPH study with the Focal One robot with HIFU technology, prompting investors to make a number of financial investments and launch an investment project.

Trotz des Potenzials von EDAP’s innovative technology war with the financial leistung of the Unternehmens herausfordernd. Laut InvestingPro-Daten believed that EDAP’s shares would be at US$66.47 million for the last month in the 2024 quarter, with a turnover of 8.79%. If the positive Wachstum is that the beach is no longer profitable, with an operating profit margin of -26.74% for the small Zeitraum.

InvestingPro-Tipps we are confident that the EDAP barmittel has studied the costs for clinical studies and product tentwicklung, which can control their costs. Because the Unternehmen put more Barmittel as Debt in the port of Bilanz, certain financial flexibility was required.

The company’s young venture is a curious one, where InvestingPro data shows a 51.15% return in the company’s trend of showing off their dating punk. Once the campaign has been completed after a period of 52 weeks, it will now reach 30% of the 52 homes.

For investors, the long-term potential of EDAP in the investment sector is a separate pipeline from the innovative pipelines that can divest their financial recovery. InvestingPro offers 12 different tips for EDAP and a nicer analysis for those years, which can take a bit in the Australian world.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.